Background Renal fibrosis is a progressive injury contributing to renal function deterioration. Mounting evidence has underscored the profound impact of gut microbiota metabolites on host health and disease, yet their underlying mechanisms against renal fibrosis remain unclear. The aim of this study was to fully elucidate their therapeutic potential in the context of renal fibrosis.
Methods The targets of gut microbiota metabolites were identified in gutMGene. The diseases targets were obtained from the OMIM, GeneCards and DisGeNet databases. The STRING and DAVID platform were employed to identify the core targets and pathways. Gut Microbiota-Targets-Pathway-Metabolites (G-T-P-M) network was constructed to screen the core metabolites. Molecular docking was used to assess the interactions between the targets and metabolites.
Results A total of 47 overlapping targets related to gut microbiota metabolites and renal fibrosis were acquired. The bioinformatics analysis indicated that the targets were enriched in the regulation of TNF pathway and Toll-like receptor pathway. The PPI network (Protein-Protein Interaction) identified JUN, IL6, IL1B and AKT1 as the core targets. The G-T-P-M network revealed that Propionate, Butyrate and 3-Indolepropionic acid were identified as the core non-toxic and promising core metabolites. The core metabolites showed stable binding affinity with the core targets.
Conclusion The findings highlight that gut microbiota metabolites represent a promising therapeutic option for combating renal fibrosis by modulating multiple targets and pathways, providing a theoretical foundation for the future studies exploring gut microbiota as targeted strategies in the prevention and treatment of renal fibrosis.
| [1] |
Abbad L, Esteve E, Chatziantoniou C. Advances and challenges in kidney fibrosis therapeutics. Nat Rev Nephrol, 2025, 21(5): 314-329.
|
| [2] |
Bai L, Chen Q, Li Y, Wu F, Jin M, Chen Y, et al.. Trimethylamine Induced Chronic Kidney Injury by Activating the ZBP1-NLRP3 Inflammasome Pathway. Physiol Res, 2024, 73(5): 779-789.
|
| [3] |
Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, et al.. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiol, 2021, 6(12): 1440-1445.
|
| [4] |
Cao G, Miao H, Wang YN, Chen DQ, Wu XQ, Chen L, et al.. Intrarenal 1-methoxypyrene, an aryl hydrocarbon receptor agonist, mediates progressive tubulointerstitial fibrosis in mice. Acta Pharmacol Sin, 2022, 43(11): 2929-2945.
|
| [5] |
Chen YC, Fang SY, Chen CL, Fang MC, Yang YY, Lee MC, et al.. Divergent immunomodulatory and gut microbiota-modulating effects of Sargassum polysaccharides and oligosaccharides in delayed-type hypersensitivity mice. Bioresour Bioprocess, 2025, 12(1): 108.
|
| [6] |
Corte-Iglesias V, Saiz ML, Andrade-Lopez AC, Salazar N, Bernet CR, Martin-Martin C, et al.. Propionate and butyrate counteract renal damage and progression to chronic kidney disease. Nephrol Dial Transpl, 2024, 40(1): 133-150.
|
| [7] |
Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F et al (2023) Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients 15(9):2211
|
| [8] |
Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. Excli j, 2021, 20: 301-319
|
| [9] |
Guijas C, Horton LE, Hoang L, Domingo-Almenara X, Billings EM, Ware BC et al (2022) Microbial Metabolite 3-Indolepropionic Acid Mediates Immunosuppression. Metabolites 12(7):645
|
| [10] |
Gungor O, Hasbal NB, Alaygut D. Trimethylamine N-oxide and kidney diseases: what do we know?. J Bras Nefrol, 2024, 46(1): 85-92
|
| [11] |
Guo X, Zhu Y, Sun Y, Li X. IL-6 accelerates renal fibrosis after acute kidney injury via DNMT1-dependent FOXO3a methylation and activation of Wnt/β-catenin pathway. Int Immunopharmacol, 2022, 109: 108746.
|
| [12] |
Han SJ, Williams RM, D’Agati V, Jaimes EA, Heller DA, Lee HT. Selective nanoparticle-mediated targeting of renal tubular Toll-like receptor 9 attenuates ischemic acute kidney injury. Kidney Int, 2020, 98(1): 76-87.
|
| [13] |
He M, Wei W, Zhang Y, Xiang Z, Peng D, Kasimumali A, et al.. Gut microbial metabolites SCFAs and chronic kidney disease. J Transl Med, 2024, 22(1): 172.
|
| [14] |
Huang L, Dai Y, Geng Z, He H, Hong F. Granulin in renal tubular epithelia is associated with interstitial inflammation and activates the TLR9-IFN-α pathway in lupus nephritis. Lupus, 2024, 33(5): 439-449.
|
| [15] |
Jere SW, Houreld NN, Abrahamse H. Photobiomodulation activates the PI3K/AKT pathway in diabetic fibroblast cells in vitro. J Photochem Photobiol B, 2022, 237: 112590.
|
| [16] |
Kaur A, Baldwin J, Brar D, Salunke DB, Petrovsky N. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr Opin Chem Biol, 2022, 70: 102172.
|
| [17] |
Liu D, Chen X, He W, Lu M, Li Q, Zhang S, et al.. Update on the Pathogenesis, Diagnosis, and Treatment of Diabetic Tubulopathy. Integr Med Nephrol Androl, 2024, 11(4): e23-00029.
|
| [18] |
Liu L, Yu QQ, Zhang YL, Zhou JT, Jin Y, Jiang CH et al (2026) Renal fibrosis is induced by hyperactive Wnt/β-catenin pathway via microbial-mediated tryptophan metabolism-driven AhR signaling in rodents and humans. Cell Mol Life Sci 83(1):182
|
| [19] |
Liu M, Zen K. Toll-Like Receptors Regulate the Development and Progression of Renal Diseases. Kidney Dis (Basel), 2021, 7(1): 14-23.
|
| [20] |
Liu Y. Kidney Fibrosis: Fundamental Questions, Challenges, and Perspectives. Integr Med Nephrol Androl, 2024, 11(4): e24-00027.
|
| [21] |
Liu ZG, Dai XS, Zhang HB, Shi RJ, Hui Y, Jin X et al (2020) Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat Commun 11(1):855
|
| [22] |
Lousa I, Reis F, Santos-Silva A, Belo L (2022) The Signaling Pathway of TNF Receptors: Linking Animal Models of Renal Disease to Human CKD. Int J Mol Sci 23(6):3284
|
| [23] |
Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol, 2024, 24(8): 577-595.
|
| [24] |
Miao H, Wang YN, Su W, Zou L, Zhuang SG, Yu XY, et al.. Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1/β-catenin pathway. Acta Pharmacol Sin, 2024, 45(1): 137-149.
|
| [25] |
O’Sullivan ED, Mylonas KJ, Xin C, Baird DP, Carvalho C, Docherty MH, et al.. Indian Hedgehog release from TNF-activated renal epithelia drives local and remote organ fibrosis. Sci Transl Med, 2023, 15(698): eabn0736.
|
| [26] |
Pan L, Cheng Y, Yang W, Wu X, Zhu H, Hu M, et al.. Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice. Inflammation, 2023, 46(4): 1531-1542.
|
| [27] |
Portincasa P, Bonfrate L, Vacca M, De Angelis M, Farella I, Lanza E et al (2022) Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci 23(3):1103
|
| [28] |
Premier Science LUK, Agha R, Mathew G, Rashid R, Kerwan A, Al-Jabir A et al (2025) Transparency In The reporting of Artificial INtelligence–the TITAN guideline. Prem J Sci 10:100082
|
| [29] |
Rong J, Zhang Z, Peng X, Li P, Zhao T, Zhong Y. Mechanisms of hepatic and renal injury in lipid metabolism disorders in metabolic syndrome. Int J Biol Sci, 2024, 20(12): 4783-4798.
|
| [30] |
Saber MM, Monir N, Awad AS, Elsherbiny ME, Zaki HF. TLR9: A friend or a foe. Life Sci, 2022, 307: 120874.
|
| [31] |
Sahoo BR. Structure of fish Toll-like receptors (TLR) and NOD-like receptors (NLR). Int J Biol Macromol, 2020, 161: 1602-1617.
|
| [32] |
Song L, Zhang W, Tang SY, Luo SM, Xiong PY, Liu JY, et al.. Natural products in traditional Chinese medicine: molecular mechanisms and therapeutic targets of renal fibrosis and state-of-the-art drug delivery systems. Biomed Pharmacother, 2024, 170: 116039.
|
| [33] |
Stoeva MK, Garcia-So J, Justice N, Myers J, Tyagi S, Nemchek M, et al.. Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease. Gut Microbes, 2021, 13(1): 1-28.
|
| [34] |
Swart IAP, Visman IM, Heslinga M, van der Horst-Bruinsma IE, van Denderen JC, Nurmohamed MT. The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study. Clin Rheumatol, 2022, 41(12): 3747-3752.
|
| [35] |
Takagaki Y, Lee SM, Dongqing Z, Kitada M, Kanasaki K, Koya D. Endothelial autophagy deficiency induces IL6 - dependent endothelial mesenchymal transition and organ fibrosis. Autophagy, 2020, 16(10): 1905-1914.
|
| [36] |
Tang G, Du Y, Guan H, Jia J, Zhu N, Shi Y, et al.. Butyrate ameliorates skeletal muscle atrophy in diabetic nephropathy by enhancing gut barrier function and FFA2-mediated PI3K/Akt/mTOR signals. Br J Pharmacol, 2022, 179(1): 159-178.
|
| [37] |
Tian X, Zeng Y, Tu Q, Jiao Y, Yao S, Chen Y et al (2023) Butyrate alleviates renal fibrosis in CKD by regulating NLRP3-mediated pyroptosis via the STING/NF-κB/p65 pathway. Int Immunopharmacol 124(Pt B):111010.
|
| [38] |
Tillett BJ, Dwiyanto J, Secombe KR, George T, Zhang V, Anderson D, et al.. SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome. Nat Commun, 2025, 16(1): 2893.
|
| [39] |
Wang W, Dernst A, Martin B, Lorenzi L, Cadefau-Fabregat M, Phulphagar K, et al.. Butyrate and propionate are microbial danger signals that activate the NLRP3 inflammasome in human macrophages upon TLR stimulation. Cell Rep, 2024, 43(9): 114736.
|
| [40] |
Wang YN, Miao H, Yu XY, Guo Y, Su W, Liu F, et al.. Oxidative stress and inflammation are mediated via aryl hydrocarbon receptor signalling in idiopathic membranous nephropathy. Free Radic Biol Med, 2023, 207: 89-106.
|
| [41] |
Yao W, Huo J, Liu K, Tao P. Exploring the beneficial effect of gut microbiota metabolites on diabetic nephropathy via network pharmacology study. Sci Rep, 2025, 15(1): 11027.
|
| [42] |
Yuan M, Sun T, Zhang Y, Guo C, Wang F, Yao Z et al (2024) Quercetin alleviates insulin resistance and repairs intestinal barrier in db/db mice by modulating gut microbiota. Nutrients 16(12):1870
|
| [43] |
Yuan X, Yang J, Huang Y, Li J, Li Y (2023) Gut Microbiota Metabolite 3-Indolepropionic Acid Directly Activates Hepatic Stellate Cells by ROS/JNK/p38 Signaling Pathways. Biomolecules 13(10):1464
|
| [44] |
Zhang B, Chen ZY, Jiang Z, Huang S, Liu XH, Wang L. Nephroprotective Effects of Cardamonin on Renal Ischemia Reperfusion Injury/UUO-Induced Renal Fibrosis. J Agric Food Chem, 2023, 71(36): 13284-13303.
|
| [45] |
Zhang W, Zhang Y, Li J, Tang J, Wu J, Xie Z, et al.. Identification of metabolites from the gut microbiota in hypertension via network pharmacology and molecular docking. Bioresour Bioprocess, 2024, 11(1): 102.
|
| [46] |
Zhang X, Zhang F, Li Y, Fan N, Zhao K, Zhang A, et al.. Blockade of PI3K/AKT signaling pathway by Astragaloside IV attenuates ulcerative colitis via improving the intestinal epithelial barrier. J Transl Med, 2024, 22(1): 406.
|
| [47] |
Zhao L, Zhang H, Li N, Chen J, Xu H, Wang Y, et al.. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. J Ethnopharmacol, 2023, 309: 116306.
|
| [48] |
Zhou X, Ji S, Chen L, Liu X, Deng Y, You Y, et al.. Gut microbiota dysbiosis in hyperuricaemia promotes renal injury through the activation of NLRP3 inflammasome. Microbiome, 2024, 12(1): 109.
|
Funding
Shanghai Famous Traditional Chinese Medicine Academic Experience Research Studio Construction Project (SHGZS-202237)
Shanghai 14th Five-Year Plan TCM Characteristic Specialty Construction Project(ZYTSZK2-13)
The Seventh Cycle Key Medical Specialty Establishment Project in Jinshan District of Shanghai (JSZK2023H04)
Shanghai District-Level Comprehensive (Specialized) Hospital's Integrated Traditional Chinese and Western Medicine Specialty Capacity(QJZXYJK-202408)
RIGHTS & PERMISSIONS
The Author(s)
PDF
